Quarterly report pursuant to Section 13 or 15(d)

Recent Developments, Liquidity and Management???s Plans (Details Narrative)

v3.23.1
Recent Developments, Liquidity and Management’s Plans (Details Narrative)
 3 Months Ended
Feb. 21, 2023
USD ($)
$ / shares
shares
Jul. 07, 2022
USD ($)
shares
Mar. 31, 2023
USD ($)
$ / shares
shares
Mar. 31, 2022
USD ($)
Feb. 23, 2023
Dec. 31, 2022
USD ($)
Dec. 31, 2021
USD ($)
Apr. 16, 2021
$ / shares
Number of shares issued | shares     550,000,000          
Share value new issues              
Preferred stock dividends     158,333        
Debt instrument fair value $ 3,149,000              
Stock issuance costs     314,311          
Fair value of the warrants     10,623,000        
Derivative liabilities     120,700          
Derivative liability fair value     3,270,500        
Issuance of warrants     762,834          
Change in Fair Value of Warrant Liabilities   $ 93,233 (1,175,000)        
Cash on hand     188,548     749,090    
Marketable securities     15,359,954     4,086,902    
Loss from operations     1,511,732 4,122,033        
Working capital     14,661,121          
Stockholders' equity     13,094,059 19,622,141   14,695,056 $ 23,647,174  
Accumulated deficit     95,428,969     93,758,904    
Net cash provided by operating activities     3,971,642 2,366,182        
Net loss     1,511,732 4,122,033        
Prepaid expenses     172,351 (222,226)        
Decrease in trade and other payables     1,304,021 (1,431,487)        
Fair value of the warrant liability   $ (93,233) 1,175,000        
Warrants [Member]                
Change in Fair Value of Warrant Liabilities     9,448,000          
Fair value of the warrant liability     (9,448,000)          
Other Operating Income (Expense) [Member]                
Change in Fair Value of Warrant Liabilities     1,175,000          
Fair value of the warrant liability     $ (1,175,000)          
Measurement Input, Default Rate [Member]                
Estimated penalty dividend rate 0.5   0.4          
Measurement Input, Option Volatility [Member]                
Estimated penalty dividend rate 120.0   125.0          
Stock price per share   131.06 125.0          
Measurement Input, Price Volatility [Member]                
Estimated penalty dividend rate 190.0   195.0          
Measurement Input, Maturity [Member]                
Warrants term 1 year 4 months 6 days   1 year 3 months          
Measurement Input, Discount Rate [Member]                
Estimated penalty dividend rate 6.8   6.4          
Stock price per share   3.07            
Measurement Input, Expected Dividend Rate [Member]                
Estimated penalty dividend rate 10.0   10.0          
Measurement Input, Lapse Rate [Member]                
Estimated penalty dividend rate 15.0   15.0          
Measurement Input, Share Price [Member]                
Exercise price | $ / shares     $ 1.72          
Measurement Input, Expected Dividend Payment [Member]                
Stock price per share     0          
Measurement Input, Risk Free Interest Rate [Member]                
Stock price per share     4.09          
Series F Convertible Preferred Stock [Member]                
Number of shares issued | shares     15,000          
Conversion of stock, description     If on any day after the issuance of the shares of Series F Preferred Stock the closing price of the Common Stock has exceeded 300% of the Conversion Price per share (subject to adjustment for stock splits, stock dividends, stock combinations, recapitalizations or other similar events) for 20 consecutive trading days and the daily dollar trading volume of the Common Stock has exceeded $3,000,000 per trading day during the same period and certain equity conditions described in the Series F Certificate of Designation are satisfied (the “Mandatory Conversion Date”), we shall deliver written notice of the Mandatory Conversion (as defined below) to all holders on the Mandatory Conversion Date and, on such Mandatory Conversion Date, we shall convert all of each holder’s shares of Series F Preferred Stock into Conversion Shares at the then effective Conversion Price (the “Mandatory Conversion”)          
Payments of financing costs     $ 14,087,111          
Series F Preferred Stock [Member]                
Share value new issues $ 3,000,000              
Conversion price | $ / shares $ 2.255   $ 2.255          
Conversion of stock, description (i) the Conversion Price then in effect and (ii) the greater of (A) 80% of the average of the three lowest closing prices of the Company’s Common Stock during the thirty trading day period immediately prior to the date the amortization payment is due or (B) the Floor Price (as defined below). For purposes of the Certificate of Designation, the “Floor Price” means the lower of (x) $0.4014 and (y) 20% of the “Minimum Price” (as defined in Rule 5635 of the Rules of the Nasdaq Stock Market) on the date of the Stockholder Approval (subject to adjustment for stock splits, stock dividends, stock combinations, recapitalizations or other similar events) or, in any case, such lower amount as permitted, from time to time, by the Nasdaq Stock Market              
Exercise price | $ / shares $ 0.4014              
Share issued price, per share | $ / shares $ 6.765              
Estimated penalty dividend rate 10   10.0          
Series F Preferred Stock [Member] | Measurement Input, Default Rate [Member]                
Estimated penalty dividend rate     15.0   15      
Securities Purchase Agreement [Member] | Institutional and Accredited Investors [Member]                
Warrants to acquire common stock | shares 6,651,885              
Securities Purchase Agreement [Member] | Institutional and Accredited Investors [Member] | Series F Convertible Preferred Stock [Member]                
Number of shares issued | shares 15,000              
Share value new issues $ 1,000              
Securities Purchase Agreement [Member] | Institutional and Accredited Investors [Member] | Series F Preferred Stock [Member]                
Conversion price | $ / shares $ 2.255              
Akers Bio Sciences Inc [Member]                
Equity percentage     22.95%          
Warrant [Member]                
Warrants shares | shares     986,486          
Number of shares issued | shares   38,265            
Warrants term   5 years 5 years          
Warrant [Member] | Measurement Input, Option Volatility [Member]                
Stock price per share     125.0          
Warrant [Member] | Measurement Input, Expected Dividend Payment [Member]                
Stock price per share     0          
Warrant [Member] | Measurement Input, Risk Free Interest Rate [Member]                
Stock price per share     3.61          
Warrant [Member] | Measurement Input, Expected Term [Member]                
Warrants term     4 years 10 months 24 days          
Common Stock [Member]                
Warrants shares | shares     4,188,315          
Share value new issues              
Derivative liability fair value     3,270,500          
Stockholders' equity     108,378,504 102,161,218   108,309,436 102,064,218  
Net loss            
Common Stock [Member] | Measurement Input, Exercise Price [Member]                
Exercise price | $ / shares $ 1.90              
Preferred Stock [Member]                
Debt instrument fair value     3,149,000          
Payments of financing costs     $ 14,087,111          
Preferred Stock [Member] | Series F Convertible Preferred Stock [Member]                
Number of shares issued | shares     15,000          
Share value new issues     $ 912,889          
Stockholders' equity     912,889    
Net loss            
MyMD Pharmaceuticals (Florida), Inc [Member]                
Common Stock, par value | $ / shares               $ 0.001
Exchange ratio price per shares | $ / shares               $ 0.7718